News

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration ...
The study mentions that formulas were collected from 899 classical books spanning over two millennia, yet there is no explanation of how these texts were selected. Were the books chosen based on their ...
[Or the word] “inclusion”—anyone who’s doing clinical trials, we have what we refer to as inclusion and exclusion criteria for participating in a trial. A lot of studies target specific populations.
Participant and context characteristics: participant inclusion criteria (age, diabetes type), diabetic retinopathy status, 34 health sector (eg, public/private/third sector) and financing of treatment ...
The inclusion and exclusion criteria for the three groups are as follows. Inclusion and Exclusion Criteria for HSCR group: 1. Patients who underwent surgical resection of the affected intestinal ...
Seqfirst-neo is the first study to use exclusion, rather than inclusion, criteria for which infants should receive genomic testing in the NICU, setting a new standard of care by enabling ...
First-ever human clinical trial of a xeno-organ intended to allow for potential registration through the submission of a Biologics License Application to the U.S. FDA First xenotransplant is expected ...
Menstrual leave alone cannot address the broader needs of menstruating workers. This is where menstrual flexibility policies come in.
To accomplish this, the pair examined the inclusion and exclusion criteria for clinical trials included in the National Health and Nutrition Examination Survey, a long-term program of studies ...
PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...